Drug · single active ingredient
Tulathromycin: adverse event reports
All products with this active ingredient · 17 FDA-approved applications in the Green Book
- Mostly cattle reports
- Subcutaneous route most often
- Brands masked by FDA
3,162 adverse event reports in FDA's database list a drug whose active ingredient is recorded as tulathromycin. The earliest was received in January 2005, the latest in March 2026. The Green Book lists 17 FDA-approved applications with this single active ingredient.
openFDA masks the brand and manufacturer in every report, so these figures describe the ingredient across all products and cannot be attributed to a brand.
In the 12 months to March 2026, 142 reports named it, down 18% from 174 in the 12 months before. FDA posts reports quarterly with a delay of three to six months, so the newest months are incomplete and usually grow in later releases. Over its whole reporting history that is about 149 reports a year and 0.2% of all 1,357,245 reports (7.3% of all cattle reports). How many animals received it is not published, so a count says nothing about how often a problem occurs per dose.
Reporters most often listed death (36.2%), lack of efficacy (bacteria) - NOS (30.5%) and lack of efficacy - NOS (26%). A report can list several signs, so shares add to more than 100%; 645 different terms appear across these reports.
71.9% of reports concern cattle. Not every report describes illness: 42.5% were filed wholly or partly as lack of expected effectiveness and 12.1% as product or packaging defects. Of reports that state seriousness, 84.6% were classed as serious, and 55.6% of all reports record a death or euthanasia as an outcome, as reported. FDA has not necessarily determined whether any drug played a part.
Monthly reports by species, five years
Reports by the month FDA received them. Each panel has its own scale; the peak month is printed at the top right. The newest months are incomplete because FDA posts reports with a delay of three to six months.
Reports by year received
2026 covers reports received through March 2026 only.
Signs listed in reports
share of tulathromycin reports listing the termall cattle reports
- Death36.2%1,145
- Lack of efficacy (bacteria) - NOS[the product did not have the expected effect: target not specified]30.5%965
- Lack of efficacy - NOS[the product did not have the expected effect]26%823
- Death-treatment failure8.4%266
- Injection site pain[pain where the injection was given]5.4%171
- Accidental exposure[exposure that was not intended]5.2%163
- Necropsy performed4.6%145
- Unclassifiable adverse event[event that fits no dictionary term]4.3%137
- Injection site swelling[swelling where the injection was given]3.6%113
- PR-lung(s), lesion(s)[legacy FDA term: lesions found in the lungs]3.1%99
- Injection site reaction NOS[reaction nos where the injection was given]3%95
- Death by euthanasia[the animal was euthanized]2.7%85
- No sign[no clinical sign was reported]2.7%85
- Containers, Abnormal[a product quality report, not a sign in an animal]2.6%81
- Unrelated death1.9%61
- Color, Abnormal[a product quality report, not a sign in an animal]1.8%57
- Other abnormal test result NOS[abnormal laboratory result, type not specified]1.7%55
- Containers, Damaged[a product quality report, not a sign in an animal]1.6%52
- Anaphylaxis[sudden severe allergic-type reaction]1.6%51
- Unexplained death1.5%46
- Vials, Damaged[a product quality report, not a sign in an animal]1.4%45
- Increased mortality rate1.4%44
- NT - Abnormal necropsy finding NOS[NOS: not otherwise specified]1.4%44
- Abnormal test result1.3%42
- Puncture wound1.3%42
- Lack of efficacy (mycoplasma) - NOS[the product did not have the expected effect: target not specified]1.3%41
- Injection site inflammation[inflammation where the injection was given]1.3%40
- Recumbency[lying down and unable or unwilling to rise]1.3%40
- Pneumonia[lung infection or inflammation]1.2%37
Top 30 of 645 coded terms (VeDDRA, the veterinary reporting dictionary; plain-language gloss in brackets). One report can list several terms. The ticks show how often the same term appears in a wider pool of reports; they describe the reports, and FDA cautions that such figures cannot be used to estimate risk or to compare one product with another. openFDA masks brand and manufacturer names in adverse event records, so the reports counted here cannot be attributed to a particular brand.
Outcomes and report types
Outcome recorded in the report
What kind of report it was
Coloured bar: reports naming tulathromycin. Grey bar: all 1,357,245 reports in the database. Outcomes are the status at the time of the last report, as stated by the reporter; a report covering several animals can carry more than one outcome. FDA has not necessarily determined whether any drug played a part in any outcome.
Species and breeds in the reports
Single-breed animals
Breed shares follow how common each breed is. Crossbred animals and reports with no breed stay in the species figure only.
Age, weight and route
Age of the animal
Weight of the animal
Route of administration stated in reports: subcutaneous (2,141), intramuscular (144), topical (25), parenteral (18), oral (16), other (12).
In context
| Measure | Tulathromycin | All cattle reports | All reports |
|---|---|---|---|
| Reports | 3,162 | 31,229 | 1,357,245 |
| Share of that pool's reports naming this drug | — | 7.3% | 0.2% |
| Classed serious, of reports stating it | 84.6% | 58.4% | 38.6% |
| Death or euthanasia recorded, per 1,000 reports | 555.7 | 368 | 63.8 |
| Filed as lack of expected effectiveness (wholly or partly) | 42.5% | — | 23% |
| Top term, share of reports | Death 36.2% | 29.4% | — |
This set accounts for 92.9% of all reports naming tulathromycin, so no separate ingredient column is shown. Shares are of reports, not of animals treated. The number of doses sold is not public, so none of these figures is a rate of occurrence, and differences between columns reflect which animals receive a drug and who reports as much as anything else.
Other ingredient sets sharing an ingredient
| Active ingredients | Reports | Latest 12 months |
|---|---|---|
| Ketoprofen + Tulathromycin | 258 | 51 |
Listed for navigation, ordered by report count. FDA states that these data "cannot be used to estimate the risk associated with the product or compare one drug or device product with another": drugs differ in formulation, in the animals they are given to, in sales volume and in years on the market. A report's ingredient field can be incomplete, so reports about one product may sit under more than one set.
FDA-approved products containing tulathromycin (Green Book)
Reference information, not report statistics. openFDA masks brand and manufacturer names in adverse event records, so the reports counted here cannot be attributed to a particular brand. The list below is the FDA Green Book as of 1 Oct 2026; nothing on this page says which of these products, if any, a report concerned.
| Trade name | Active ingredients | Sponsor | Approved for | Application |
|---|---|---|---|---|
| Draxxin | Tulathromycin | Zoetis Inc. | Cattle, Swine | NADA 141-244 |
| Draxxin 25 Injectable Solution | Tulathromycin | Zoetis Inc. | Cattle, Swine | NADA 141-349 |
| Macrosyn | Tulathromycin | Bimeda Animal Health Ltd. | Cattle, Swine | ANADA 200-657 |
| Increxxa 25 | Tulathromycin | Elanco US Inc. | Cattle, Swine | ANADA 200-665 |
| Increxxa | Tulathromycin | Elanco US Inc. | Cattle, Swine | ANADA 200-666 |
| Tulissin 25 | Tulathromycin | Virbac AH, Inc. | Cattle, Swine | ANADA 200-668 |
| Tulissin 100 | Tulathromycin | Virbac AH, Inc. | Cattle, Swine | ANADA 200-669 |
| Tulaven 100 | Tulathromycin | Ceva Sante Animale | Cattle, Swine | ANADA 200-711 |
| Tulaven 25 | Tulathromycin | Ceva Sante Animale | Cattle, Swine | ANADA 200-712 |
| Arovyn | Tulathromycin | Intervet, Inc. | Cattle, Swine | ANADA 200-715 |
| Tulieve | Tulathromycin | Norbrook Laboratories, Ltd. | Cattle, Swine | ANADA 200-723 |
| RESPIRmycin | Tulathromycin | Parnell Technologies Pty. Ltd. | Cattle, Swine | ANADA 200-730 |
| Tulathromycin Injection | Tulathromycin | Hikma Pharmaceuticals USA, Inc. | Cattle, Swine | ANADA 200-742 |
| RESPIRmycin 25 | Tulathromycin | Parnell Technologies Pty. Ltd. | Cattle, Swine | ANADA 200-745 |
| Tulaject 100 | Tulathromycin | Cronus Pharma Specialities India Private Ltd. | Cattle, Swine | ANADA 200-773 |
| Tulaject | Tulathromycin | Cronus Pharma Specialities India Private Ltd. | Cattle, Swine | ANADA 200-774 |
| Macrosyn 25 | Tulathromycin | Bimeda Animal Health Ltd. | Cattle, Swine | ANADA 200-844 |
Species are the major species the Green Book search lists for the application ("—" where it lists another species or none). Approval dates are not part of the Green Book listing files and are not shown. Pioneer applications (NADA) come first, then generics (ANADA).
Questions about tulathromycin reports
How many adverse event reports has FDA received for tulathromycin?
3,162 reports record a drug with tulathromycin as its active ingredient in the openFDA release of 28 Sep 2026, covering reports received through March 2026. 142 of them arrived in the latest 12 months.
Which brand do these reports concern?
That cannot be known from the public data. openFDA masks brand and manufacturer names in adverse event records, so the reports counted here cannot be attributed to a particular brand. The Green Book lists 17 approved applications with this ingredient alone; the reference list on this page names them without any counts.
What signs are reported most often?
death (36.2%), lack of efficacy (bacteria) - NOS (30.5%), lack of efficacy - NOS (26%), death-treatment failure (8.4%) and injection site pain (5.4%). These are the coded terms listed in reports; several can appear in one report, and a term's presence is not a finding that the drug was responsible.
Which species and breeds appear in these reports?
cattle (71.9%), human exposure (10.8%) and pig (2.5%). Among single-breed animals the most frequent labels are Holstein-Friesian, Aberdeen Angus, Jersey and Hereford cattle; popular breeds appear often in any drug's reports because there are more of them.
Are reports rising?
142 reports in the 12 months to March 2026, down 18% from 174 in the 12 months before. FDA posts reports quarterly with a delay of three to six months, so the newest months are incomplete and usually grow in later releases. Counts also move with sales, publicity and time on the market.
Do these reports show that tulathromycin harms pets?
Report counts cannot show that. FDA states that "there is no certainty that the reported drug or device caused the adverse event" and that the event "may have been related to an underlying disease, other drugs used at the same time or other non-drug related sources." FDA also notes that commonly used products may have more reports simply because more animals receive them.
Are these the side effects of tulathromycin?
They are signs listed in reports, not an established list of side effects. The adverse reactions observed in studies are printed on each product's FDA-approved label, which a veterinarian can go through with you. This page is a record of what was reported to FDA.
How do I report a problem with an animal drug?
FDA asks owners and veterinarians to call the drug company first (the number is on the label); companies must pass reports to FDA. Reports can also go directly to FDA on Form FDA 1932a. See the guide on how to report.
Where this comes from. Counts are built from the openFDA Animal & Veterinary adverse event bulk files released 28 Sep 2026, which hold reports FDA's Center for Veterinary Medicine received through 31 Mar 2026. openFDA masks brand and manufacturer names in these files, so drugs are counted by the active ingredients each record discloses and no figure is attributed to a brand, application or company. Ingredient names, and the separate reference lists of approved products, follow the FDA Green Book as of 1 Oct 2026. Drug entries are grouped by the active ingredients their unmasked ingredient field discloses; the application number that records also carry is not used. No report text, lot numbers or reporter details are published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.